Literature DB >> 7632611

Progression to steroid autonomy is accompanied by altered sensitivity to growth factors in S115 mouse mammary tumour cells.

R J Daly1, N Carrick, P D Darbre.   

Abstract

Progression to steroid autonomy is a major clinical problem in the treatment of steroid-sensitive tumours. Molecular mechanisms remain unknown but recent hypotheses imply a role for growth factors in this progression. Since S115 + A androgen-responsive mouse mammary tumour cells provide a model system to study this phenomenon in vitro, we have used this model to investigate growth factor gene expression and sensitivity during progression from a steroid sensitive to insensitive state. S115 + A androgen-responsive cells showed a positive proliferative response, morphological response and increased saturation density to various forms of fibroblast growth factor (FGF) and transforming growth factor beta (TGF beta) in both monolayer and suspension culture. A marked synergy was noted, however, between FGF and TGF beta in promoting growth in suspension culture. S115 + A cells possessed mRNA for both acidic FGF (aFGF) and TGF beta 1, both of which were increased by testosterone. Progression to androgen insensitivity was associated with a reversal of growth factor response such that all growth factor responses became generally inhibitory on growth of the unresponsive cells but with a particularly striking synergistic action between FGF and TGF beta 1 on inhibition of both monolayer and suspension growth. Levels of aFGF and TGF beta 1 mRNAs remained low in steroid-insensitive S115-A cells, indicating that loss of response was not associated with any constitutive upregulation of endogenous production of one of these growth factors. The scientific and clinical implications are discussed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7632611     DOI: 10.1016/0960-0760(95)00119-k

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  2 in total

1.  Priming hMSCs with a putative anti-cancer compound, myrtucommulone-a: a way to harness hMSC cytokine expression via modulating PI3K/Akt pathway?

Authors:  Banu Iskender; Kenan Izgi; Cagri Sakalar; Halit Canatan
Journal:  Tumour Biol       Date:  2015-09-03

Review 2.  Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer.

Authors:  R I Nicholson; J M Gee
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.